BioCentury | Jul 25, 2019
Company News

As Vertex broadens remit, Leiden handing baton to Kewalramani

As Vertex continues to push its pipeline beyond cystic fibrosis, it will do so with a new president and CEO at the helm. Chairman, President and CEO Jeffrey Leiden will step down from his position...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...vs. placebo in both populations. Cell therapy improves bone fusion in lumbar spinal fusion patients Bone Therapeutics S.A....
...RG7159 (Compound #), GA101 (Compound #), obinutuzumab (Generic) Molgradex nemorexant (ACT-541468) NKTR-358 RSLV-132 SEL-212 Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli...
BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
BioCentury | Nov 9, 2018
Clinical News

Bone stops Phase III of Preob cells in osteonecrosis for futility

...allogeneic platform, Allob, which is in the clinic for delayed union fractures and spinal fusion. Bone Therapeutics S.A....
...progression to fracture stage at 24 months Status: Phase III discontinued Milestone: NA Brian Moy Bone-forming cells, Preob Bone Therapeutics S.A....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Inc. (NASDAQ:BLUE) / Celgene Corp. (NASDAQ:CELG) bb21217 Relapsed/refractory multiple myeloma Ph I CRB-402 data December Bone Therapeutics S.A....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...PKU) in patients who have uncontrolled blood phenylalanine levels on existing management Submit MAA 1Q18 Bone Therapeutics S.A....
BioCentury | Oct 27, 2017
Clinical News

Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

...In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with...
...3 months and a maximum of 7 months. Allob is an allogeneic osteoblastic cell therapy. Bone Therapeutics S.A....
...pain at fracture site, weight-bearing and healing progression Status: Interim Phase I/IIa data Milestone: NA Alicia Parker Allob Bone Therapeutics S.A....
BioCentury | Oct 24, 2016
Clinical News

Allob: Additional Phase IIa data

...Bone previously reported data from the first patient in the trial (see BioCentury, March 7). Bone Therapeutics S.A....
BioCentury | Oct 11, 2016
Company News

Management tracks

...Musculoskeletal company Bone Therapeutics S.A. (Euronext:BOTHE) said CEO Enrico Bastianelli will depart for personal reasons. CBO Thomas Lienard...
BioCentury | May 9, 2016
Clinical News

Allob: Completed Phase IIa enrollment

...late February, the company reported data from the first patient treated (see BioCentury, March 7). Bone Therapeutics S.A....
Items per page:
1 - 10 of 29
BioCentury | Jul 25, 2019
Company News

As Vertex broadens remit, Leiden handing baton to Kewalramani

As Vertex continues to push its pipeline beyond cystic fibrosis, it will do so with a new president and CEO at the helm. Chairman, President and CEO Jeffrey Leiden will step down from his position...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...vs. placebo in both populations. Cell therapy improves bone fusion in lumbar spinal fusion patients Bone Therapeutics S.A....
...RG7159 (Compound #), GA101 (Compound #), obinutuzumab (Generic) Molgradex nemorexant (ACT-541468) NKTR-358 RSLV-132 SEL-212 Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli...
BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
BioCentury | Nov 9, 2018
Clinical News

Bone stops Phase III of Preob cells in osteonecrosis for futility

...allogeneic platform, Allob, which is in the clinic for delayed union fractures and spinal fusion. Bone Therapeutics S.A....
...progression to fracture stage at 24 months Status: Phase III discontinued Milestone: NA Brian Moy Bone-forming cells, Preob Bone Therapeutics S.A....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Inc. (NASDAQ:BLUE) / Celgene Corp. (NASDAQ:CELG) bb21217 Relapsed/refractory multiple myeloma Ph I CRB-402 data December Bone Therapeutics S.A....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...PKU) in patients who have uncontrolled blood phenylalanine levels on existing management Submit MAA 1Q18 Bone Therapeutics S.A....
BioCentury | Oct 27, 2017
Clinical News

Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

...In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with...
...3 months and a maximum of 7 months. Allob is an allogeneic osteoblastic cell therapy. Bone Therapeutics S.A....
...pain at fracture site, weight-bearing and healing progression Status: Interim Phase I/IIa data Milestone: NA Alicia Parker Allob Bone Therapeutics S.A....
BioCentury | Oct 24, 2016
Clinical News

Allob: Additional Phase IIa data

...Bone previously reported data from the first patient in the trial (see BioCentury, March 7). Bone Therapeutics S.A....
BioCentury | Oct 11, 2016
Company News

Management tracks

...Musculoskeletal company Bone Therapeutics S.A. (Euronext:BOTHE) said CEO Enrico Bastianelli will depart for personal reasons. CBO Thomas Lienard...
BioCentury | May 9, 2016
Clinical News

Allob: Completed Phase IIa enrollment

...late February, the company reported data from the first patient treated (see BioCentury, March 7). Bone Therapeutics S.A....
Items per page:
1 - 10 of 29